Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amneal Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for IPX203 to treat Parkinson’s disease (PD).
Amneal seeks FDA approval for IPX203 an oral formulation of CD/LD extended-release capsules to treat Parkinson’s disease. Credit: Steve Buissinne from Pixabay.
Subscribe to our email newsletter
IPX203 is a new oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules that comprises extended-release (ER) coated beads and immediate-release (IR) granules.
The company’s NDA submission is based on the data obtained from the pivotal Phase III RISE-PD clinical trial, which was conducted at 105 clinical locations in the US and European countries, including Spain, Czechia, Poland, the UK, France, Italy, and Germany.
The double-blind, multicentre, parallel-group, double-dummy, randomised, active-controlled RISE-PD clinical trial has assessed the IPX203 CD/LD extended-release capsules’ safety and efficacy compared with immediate-release CD/LD to treat PD patients with motor fluctuations.
The study showed more “Good On” time even when IPX203 was given on average three times a day, as against immediate-release CD/LD given on average five times a day.
“Good On” time is referred as the sum of “On” time with non-troublesome dyskinesia and without dyskinesia.
The findings demonstrated that the participants who received IPX203 had significantly less “off” time compared with immediate-release CD/LD.
Amneal Pharmaceuticals co-chief executive officer Chintu Patel said: “We are committed to furthering the advancement of treatments that can provide longer-lasting duration of benefit with every dose and simplify medication regimens.
“The RISE-PD data indicate IPX203 can offer patients a new and important treatment option that will enable them to have more “Good On” time during the day, which we believe would be a significant new benefit for Parkinson’s patients. We are working with the FDA to bring this treatment to market.”
